Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212578 | 0.94 | HDAC2 (0.52) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL15468834 | 0.84 | — | — | |
| SCHEMBL22639538 | 0.80 | HDAC4 (0.44) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL19743540 | 0.79 | FFAR1 (0.31) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL19743538 | 0.79 | FFAR1 (0.31) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL19743539 | 0.79 | FFAR1 (0.31) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL14490188 | 0.79 | HDAC2 (0.50) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL24995580 | 0.78 | HDAC3 (0.33) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL28275218 | 0.78 | HDAC4 (0.46) | HDAC2HDAC4HDAC8HDAC6HDAC3 | |
| SCHEMBL16850492 | 0.75 | HDAC2 (0.62) | HDAC2HDAC4HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2021219072-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2021-08-12 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200316068-A1 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| US-8420145-B2 | Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20080214668-A1 | USE OF RETINOIDS TO TREAT HIGH BLOOD PRESSURE AND OTHER CARDIOVASCULAR DISEASE | OREGON HEALTH AND SCIENCES UNIVERSITY (US) | 2008-09-04 | — | — | US | disclosed |
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | LARSEN LARS M | 2007-10-25 | — | — | US | disclosed |
| US-20070154981-A1 | Insulin-producing cells derived from stem cells | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1727529-A2 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | Larsen, Lars, Michael (DK) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005087210-A2 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | LARSEN LARS MICHAEL (DK) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005045001-A2 | INSULIN-PRODUCING CELLS DERIVED FROM STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20030008919-A1 | Use of retinoids to treat high blood pressure and other cardiovascular disease | ROULLET JEAN-BAPTISTE (US) | 2003-01-09 | — | — | US | disclosed |
| US-6437003-B1 | STROKES | ROULLET JEAN-BAPTISTE (US) | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | HDAC2 808/4885HDAC4 1128/4885HDAC8 929/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | HDAC2 808/4885HDAC4 1128/4885HDAC8 929/4885 |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | HDAC2 3628/4885HDAC4 2232/4885HDAC8 3409/4885 |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | HDAC2 3525/4885HDAC4 2186/4885HDAC8 3353/4885 |
| US-20200316068-A1 | Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, LCK, SYK | HDAC2 1120/4885HDAC4 1690/4885HDAC8 2040/4885 |
| US-20030008919-A1 | Use of retinoids to treat high blood pressure and other cardiovascular disease | RARA, RXRA, RARB | HDAC2 1544/4885HDAC4 778/4885HDAC8 832/4885 |
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | VEGFA, HIF1AN, ALDH1A2 | HDAC2 1915/4885HDAC4 1379/4885HDAC8 1698/4885 |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | TAS2R10, TAS2R41, TAS2R30 | HDAC2 2623/4885HDAC4 2415/4885HDAC8 3608/4885 |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | CDK1, CDK11A, CDK12 | HDAC2 908/4885HDAC4 967/4885HDAC8 970/4885 |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | HDAC2 3318/4885HDAC4 4334/4885HDAC8 4593/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | HDAC2 1239/4885HDAC4 1852/4885HDAC8 1187/4885 |
| US-20080214668-A1 | USE OF RETINOIDS TO TREAT HIGH BLOOD PRESSURE AND OTHER CARDIOVASCULAR DISEASE | RARA, RXRA, RARB | HDAC2 1544/4885HDAC4 778/4885HDAC8 832/4885 |
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | HDAC2 950/4885HDAC4 1419/4885HDAC8 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.